Vera Ebit Per Revenue vs Capex To Revenue Analysis

VERA Stock

USD 49.75 0.92 1.88%

Vera Therapeutics financial indicator trend analysis is much more than just breaking down Vera Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vera Therapeutics is a good investment. Please check the relationship between Vera Therapeutics Ebit Per Revenue and its Capex To Revenue accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vera Therapeutics Ebit Per Revenue account and Capex To Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Vera Therapeutics' Ebit Per Revenue and Capex To Revenue is -0.79. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Capex To Revenue in the same time period over historical financial statements of Vera Therapeutics, assuming nothing else is changed. The correlation between historical values of Vera Therapeutics' Ebit Per Revenue and Capex To Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Vera Therapeutics are associated (or correlated) with its Capex To Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capex To Revenue has no effect on the direction of Ebit Per Revenue i.e., Vera Therapeutics' Ebit Per Revenue and Capex To Revenue go up and down completely randomly.

Correlation Coefficient

-0.79

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Ebit Per Revenue

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.

Most indicators from Vera Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vera Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.The current year's Enterprise Value is expected to grow to about 508.5 M, whereas Tax Provision is forecasted to decline to 800.00.

Vera Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross
Total Assets		0.87	0.93	0.95	0.85	-0.27	0.85	0.55	0.95	-0.39	-0.95	0.92	0.83	0.63	0.97	-0.72	1.0	0.97	0.85	0.02	0.82	0.95	0.96	0.28	0.88	0.55
Short Long Term Debt Total	0.87		0.76	0.85	0.88	-0.59	0.85	0.61	0.73	0.02	-0.97	0.86	0.61	0.65	0.8	-0.86	0.86	0.87	1.0	-0.06	0.76	0.87	0.83	0.16	0.93	0.61
Other Current Liab	0.93	0.76		0.93	0.89	-0.22	0.9	0.57	0.88	-0.59	-0.86	0.87	0.93	0.68	0.96	-0.52	0.93	0.91	0.74	-0.19	0.82	0.91	0.95	0.07	0.88	0.57
Total Current Liabilities	0.95	0.85	0.93		0.86	-0.47	0.86	0.79	0.82	-0.4	-0.89	0.99	0.82	0.84	0.92	-0.55	0.93	0.93	0.85	-0.13	0.95	1.0	0.92	0.15	0.87	0.79
Total Stockholder Equity	0.85	0.88	0.89	0.86		-0.5	1.0	0.56	0.71	-0.22	-0.89	0.8	0.72	0.67	0.81	-0.67	0.85	0.91	0.86	-0.43	0.73	0.86	0.93	-0.2	0.99	0.56
Other Liab	-0.27	-0.59	-0.22	-0.47	-0.5		-0.49	-0.78	0.04	-0.45	0.42	-0.54	0.0	-0.75	-0.13	0.26	-0.23	-0.39	-0.61	0.5	-0.58	-0.49	-0.32	0.37	-0.53	-0.78
Net Tangible Assets	0.85	0.85	0.9	0.86	1.0	-0.49		0.56	0.71	-0.25	-0.88	0.8	0.73	0.68	0.81	-0.63	0.84	0.91	0.83	-0.46	0.73	0.86	0.93	-0.22	0.99	0.56
Property Plant And Equipment Net	0.55	0.61	0.57	0.79	0.56	-0.78	0.56		0.31	-0.13	-0.55	0.83	0.45	0.98	0.51	-0.14	0.52	0.57	0.64	-0.28	0.92	0.77	0.53	-0.05	0.57	1.0
Current Deferred Revenue	0.95	0.73	0.88	0.82	0.71	0.04	0.71	0.31		-0.51	-0.86	0.78	0.84	0.39	0.96	-0.7	0.96	0.87	0.71	0.23	0.65	0.83	0.88	0.46	0.73	0.31
Net Debt	-0.39	0.02	-0.59	-0.4	-0.22	-0.45	-0.25	-0.13	-0.51		0.17	-0.31	-0.77	-0.22	-0.56	-0.2	-0.39	-0.26	0.03	-0.06	-0.37	-0.33	-0.37	-0.18	-0.16	-0.13
Retained Earnings	-0.95	-0.97	-0.86	-0.89	-0.89	0.42	-0.88	-0.55	-0.86	0.17		-0.88	-0.74	-0.61	-0.91	0.85	-0.94	-0.92	-0.97	0.0	-0.78	-0.91	-0.9	-0.24	-0.93	-0.55
Accounts Payable	0.92	0.86	0.87	0.99	0.8	-0.54	0.8	0.83	0.78	-0.31	-0.88		0.75	0.87	0.88	-0.55	0.9	0.9	0.86	-0.08	0.97	0.99	0.87	0.2	0.83	0.83
Cash	0.83	0.61	0.93	0.82	0.72	0.0	0.73	0.45	0.84	-0.77	-0.74	0.75		0.56	0.93	-0.39	0.83	0.72	0.6	0.01	0.74	0.78	0.79	0.24	0.7	0.45
Non Current Assets Total	0.63	0.65	0.68	0.84	0.67	-0.75	0.68	0.98	0.39	-0.22	-0.61	0.87	0.56		0.59	-0.18	0.59	0.65	0.67	-0.37	0.94	0.83	0.63	-0.13	0.67	0.98
Non Currrent Assets Other	0.97	0.8	0.96	0.92	0.81	-0.13	0.81	0.51	0.96	-0.56	-0.91	0.88	0.93	0.59		-0.64	0.97	0.9	0.79	0.09	0.8	0.91	0.91	0.34	0.82	0.51
Other Assets	-0.72	-0.86	-0.52	-0.55	-0.67	0.26	-0.63	-0.14	-0.7	-0.2	0.85	-0.55	-0.39	-0.18	-0.64		-0.73	-0.72	-0.84	-0.2	-0.37	-0.59	-0.66	-0.33	-0.74	-0.14
Cash And Short Term Investments	1.0	0.86	0.93	0.93	0.85	-0.23	0.84	0.52	0.96	-0.39	-0.94	0.9	0.83	0.59	0.97	-0.73		0.97	0.85	0.04	0.79	0.94	0.96	0.3	0.87	0.52
Common Stock Shares Outstanding	0.97	0.87	0.91	0.93	0.91	-0.39	0.91	0.57	0.87	-0.26	-0.92	0.9	0.72	0.65	0.9	-0.72	0.97		0.85	-0.17	0.78	0.95	0.99	0.09	0.92	0.57
Short Term Investments	0.85	1.0	0.74	0.85	0.86	-0.61	0.83	0.64	0.71	0.03	-0.97	0.86	0.6	0.67	0.79	-0.84	0.85	0.85		-0.04	0.78	0.87	0.81	0.18	0.91	0.64
Non Current Liabilities Total	0.02	-0.06	-0.19	-0.13	-0.43	0.5	-0.46	-0.28	0.23	-0.06	0.0	-0.08	0.01	-0.37	0.09	-0.2	0.04	-0.17	-0.04		-0.13	-0.12	-0.24	0.96	-0.35	-0.28
Capital Lease Obligations	0.82	0.76	0.82	0.95	0.73	-0.58	0.73	0.92	0.65	-0.37	-0.78	0.97	0.74	0.94	0.8	-0.37	0.79	0.78	0.78	-0.13		0.94	0.76	0.15	0.74	0.92
Other Current Assets	0.95	0.87	0.91	1.0	0.86	-0.49	0.86	0.77	0.83	-0.33	-0.91	0.99	0.78	0.83	0.91	-0.59	0.94	0.95	0.87	-0.12	0.94		0.93	0.16	0.88	0.77
Other Stockholder Equity	0.96	0.83	0.95	0.92	0.93	-0.32	0.93	0.53	0.88	-0.37	-0.9	0.87	0.79	0.63	0.91	-0.66	0.96	0.99	0.81	-0.24	0.76	0.93		0.02	0.93	0.53
Total Liab	0.28	0.16	0.07	0.15	-0.2	0.37	-0.22	-0.05	0.46	-0.18	-0.24	0.2	0.24	-0.13	0.34	-0.33	0.3	0.09	0.18	0.96	0.15	0.16	0.02		-0.12	-0.05
Net Invested Capital	0.88	0.93	0.88	0.87	0.99	-0.53	0.99	0.57	0.73	-0.16	-0.93	0.83	0.7	0.67	0.82	-0.74	0.87	0.92	0.91	-0.35	0.74	0.88	0.93	-0.12		0.57
Property Plant And Equipment Gross	0.55	0.61	0.57	0.79	0.56	-0.78	0.56	1.0	0.31	-0.13	-0.55	0.83	0.45	0.98	0.51	-0.14	0.52	0.57	0.64	-0.28	0.92	0.77	0.53	-0.05	0.57

Click cells to compare fundamentals

Vera Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:

How To Invest In Vera

Details

Is Vera Stock a good investment?

Details

What is Vera Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vera Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.

You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.61)

Return On Assets

(0.33)

Return On Equity

(0.65)

The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Vera Ebit Per Revenue vs Capex To Revenue Analysis

Ebit Per Revenue vs Capex To Revenue

Ebit Per Revenue vs Capex To Revenue Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Capex To Revenue

Vera Therapeutics fundamental ratios Correlations

Vera Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Short Term Investments	+ 1.0	Short Long Term Debt Total
Other Current Assets	+ 1.0	Total Current Liabilities
Net Tangible Assets	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Accounts Payable	+ 0.99	Total Current Liabilities

Short Term Investments	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Short Long Term Debt Total
Retained Earnings	- 0.95	Total Assets
Cash And Short Term Investments	- 0.94	Retained Earnings
Net Invested Capital	- 0.93	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings